Maenosono Ryoichi, Matsunaga Tomohisa, Hirano Hajime, Nomi Hayahito, Taniguchi Shunri, Fujiwara Yuya, Minami Koichiro, Uehara Hirofumi, Inamoto Teruo, Azuma Haruhito
Department of Urology, Osaka Medical College, Osaka, Japan.
Department of Urology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
Case Rep Transplant. 2020 Jul 16;2020:1780760. doi: 10.1155/2020/1780760. eCollection 2020.
Despite the evolution of transplantation techniques, urological complications are common and result in loss of graft. We report the case of a 57-year-old man who developed continuous urine leakage despite pyeloureteral neoanastomosis and stenting after kidney transplantation from his dizygotic twin. Suspecting ureteral leakage, we performed pyeloureteral neoanastomosis using his native right ureter and a ureteral stent 5 days after the kidney transplant. However, urine leakage continued for several days. Because the plasma factor XIII level decreased to 48%, we administered factor XIII products (Fibrogammin P; CSL Behring, King of Prussia, PA) after the surgery. Although its utility and safety in patients with renal failure and/or transplantation are unclear, urine leakage stopped after the infusion of fibrogammin without any side effects. This is the first case report of the use of factor XIII for refractory urine leakage after kidney transplantation. Although further studies are needed, administration of factor XIII products could be one option for refractory urine leakage after transplantation.
尽管移植技术不断发展,但泌尿系统并发症仍很常见,并导致移植肾丧失。我们报告了一例57岁男性病例,该患者在接受来自其异卵双胞胎的肾脏移植后,尽管进行了肾盂输尿管再吻合术和支架置入术,但仍出现持续性尿漏。怀疑输尿管漏,我们在肾移植术后5天使用其右侧自体输尿管和输尿管支架进行了肾盂输尿管再吻合术。然而,尿漏持续了数天。由于血浆凝血因子 XIII 水平降至48%,我们在手术后给予了凝血因子 XIII 产品(Fibrogammin P;CSL Behring,宾夕法尼亚州普鲁士王镇)。尽管其在肾衰竭和/或移植患者中的效用和安全性尚不清楚,但输注纤维蛋白原后尿漏停止,且无任何副作用。这是首例关于凝血因子 XIII 用于肾移植后难治性尿漏的病例报告。尽管需要进一步研究,但给予凝血因子 XIII 产品可能是移植后难治性尿漏的一种选择。